

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, April 10, 2024 – 12:00 PM – 1:30 PM

Present: Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Christopher Hughes, Dr. Venkateswara Davuluri, Dr. Kolin Good, Grace Robinson (CHC Participant)

Absent: Dr. Mahmood Usman

Non-Voting Members: Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Evan Sebastian (Pharmacy), George Kimbrow (Clinical Policy Coordinator), Heather Clarke (Director of Case Management).

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:16 PM.

Next Meeting: Wednesday, July 10, 2024 – 12:00 PM

Submitted By: Shalyn Kline (PHW Pharmacy)

Committee Chair: _____



Date: 07/10/2024

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

| Agenda Item | Discussion/Recommendation | Action | Next Steps | Owner |
|---|---|--|------------|--------------|
| I. Introduction & Call to Order | Jason called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM. | Meeting Called to Order | | Jason Skaria |
| A. Introductions | No new introductions | | | Jason Skaria |
| B. Announcements | <p>Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p> | No action required or taken. | | Jason Skaria |
| C. Explanation of the Review and Approval Process | <ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania’s Review and Approval Process | No action required or taken. | | Jason Skaria |
| D. Charter Review | The committee charter was reviewed with the committee members. | No action required or taken. | | Jason Skaria |
| II. Approval of Meeting Minutes | <p>A vote was taken for the approval of the minutes from Q1_2024. No objections were made.</p> <p>Motion to approve: Jill Schaeffer, RN Second motion to approve: Dr. Christopher Hughes</p> | Adoption of Q1_2024 Meeting Minutes recorded as approved | | Shalyn Kline |
| III. Old Business | No old business | No action required or taken. | | Shaly Kline |

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

| | | | | |
|---|---|---|--|---------------------|
| <p>A. Policy Submission Status</p> | <p>There are 0 outstanding clinical policies awaiting approval. Three clinical policies were denied: Beyfortus due to being part of Vaccine for Children program Daxxify will be included on the PDL under Botulinum toxins Agamree will be included one the PDL under Glucocorticoids, Oral</p> | <p>No action required or taken.</p> | | <p>Shalyn Kline</p> |
| <p>IV. New Business</p> | | | | |
| <p>A. Statewide PDL updates</p> | <p>According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.</p> | | | <p>Jason Skaria</p> |
| <p>B. Provider Education</p> | <p>A vote was taken for the approval of the Humira Biosimilars provider education. No objections were made. Motion to approve: Dr. Christopher Hughes Second motion to approve: Jill Schaeffer, RN</p> | <p>The provider education was Committee approved.</p> | | <p>Shalyn Kline</p> |
| <p>C. FDA Updates</p> | <p>This is informational only and addresses recalls, new drugs, etc. No vote necessary.</p> | <p>Informational</p> | | <p>Shalyn Kline</p> |
| <p>D. Guidelines – Drug Coverage Criteria</p> | <p>Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 7 new policies created, 26 policies had clinically significant change, 52 policies with no significant changes and 0 policies being replaced/retired for Medicaid. No objections, concerns or comments were made. Motion to approve: Michelle Bennett, RPh Second motion to approve: Dr. Venkateswara Davuluri On February 2, Opioid Use Disorder policy was updated</p> | <p>The policy revisions were Committee approved.</p> | | <p>Shalyn Kline</p> |

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

| | | | | |
|---|--|---|--|----------------|
| E. Policies and Procedures | <p>A vote was taken for the approval of the Pharmacy Policy & Procedures: PA.PHARM.02 Pharmacy & Therapeutics Committee & PA.PHARM.16 Lost, Stolen, Spilled or Broken Medications</p> <p>Motion to approve: Dr. Christopher Hughes Second motion to approve: Dr. Venkateswara Davuluri</p> | The policy & procedure revisions were Committee approved. | | Shalyn Kline |
| F. Quantity Limit List | <p>This is a new ask from the state and will be posted to the website once approved. A vote was taken for the approval of the Quantity Limit List.</p> <p>Motion to approve: Dr. Christopher Hughes Second motion to approve: Dr. Venkateswara Davuluri</p> | The quantity limit list was Committee approved. | | Shalyn Kline |
| G. Highlights of New Medications/ Significant Changes | <p>Shalyn reviewed changes made to the Opioid Use Disorder Treatment guidelines (removal of criteria for doses of buprenorphine over 24mg/day) and quantity limit removal of presented products. Shalyn reviewed new Sickle Cell & Beta Thalassemia Gene Therapies and will be covered under a state policy, which will be presented in the May 16th DUR Board.</p> | No action required or taken. | | Shalyn Kline |
| H. Complaints and Grievances Review | <p>Shalyn stated that there was 2 determinations upheld and 1 overturned, 0 withdrawn during pre-grievance and 1 case is pending resolution. Zero determinations were for opioids, 3 were for GLP-1 Agonists. GLP-1 agonists can be indicated for obesity, diabetes or reduce risk of major adverse cardiovascular events (MACE) in overweight or obesity</p> | No action required or taken. | | Shalyn Kline |
| I. Drug Utilization Review | <p>Evan presented the drug utilization review, noted the numbers are for January-March. Retrospective Drug Utilization Review: 2641 participants reviewed, 1189 potential issues found, 17 resolutions Excessive Use of SABA: 157 provider outreaches and 2 resolutions</p> | No action required or taken. | | Evan Sebastian |
| J. PBM Oversight | <p>Jason reviewed prior authorization audits of Centene Pharmacy Solutions (CPS) continuation of monitoring of prior authorization denials, and biweekly meetings to address any findings. Jason stated that the overall pass rates was about 95%. The PBM call center and</p> | | | Jason Skaria |

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

| | | | | |
|------------------------|--|------------------------------|--|--------------|
| | prior authorization metrics were reviewed and it was found that all metrics were met, and that there was only 0 outlier for Turn-Around-Time in the last quarter. March data is not yet available. | | | |
| K. Drug Price Disputes | Shalyn presented drug price disputes for Q1. There were a total of 4 (0.0023% of claims) first-level, 2 were approved. There were no second-level disputes. | No action required or taken. | | Shalyn Kline |
| L. Open Forum | Shalyn asked if anyone had anything they would like to see presented at P&T, if they had any questions. No comment from the committee | No action required or taken. | | Shalyn Kline |
| Adjournment | The meeting was adjourned by Jason Skaria at 12:16 pm | Meeting adjourned | | Jason Skaria |

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).